Elite in Cholangiocarcinoma (Bile Duct Cancer)

Dr. Mitesh J. Borad

Hematology Oncology | Oncology
Mayo Clinic Arizona
13400 E Shea Blvd, 
Scottsdale, AZ 
 (1425 mi)
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Elite in Cholangiocarcinoma (Bile Duct Cancer)
Mayo Clinic Arizona
13400 E Shea Blvd, 
Scottsdale, AZ 
 (1425 mi)
OverviewInsuranceLocationsClinical Research

Overview

Mitesh Borad is a Hematologist Oncology specialist and an Oncologist in Scottsdale, Arizona. Mr. Borad and is rated as an Elite provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Cancer, Gallbladder Adenocarcinoma, Gallbladder Cancer, and Tissue Biopsy.

His clinical research consists of co-authoring 222 peer reviewed articles and participating in 20 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 64 articles and participated in 10 clinical trials in the study of Cholangiocarcinoma (Bile Duct Cancer).

Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
Mayo Clinic Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna

Locations

MAYO CLINIC ARIZONA
13400 E Shea Blvd, Scottsdale, AZ 85259

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

19 Clinical Trials

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Select Solid Tumors
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Select Solid Tumors
Enrollment Status: Recruiting
Publish Date: October 02, 2024
Intervention Type: Biological
Study Drugs: VV1, Cemiplimab
Study Phase: Phase 2
Phase I Trial of Intratumoral Injection of Vesicular Stomatitis Virus Expressing Human Interferon Beta in Patients With Sorafenib Refractory/Intolerant Hepatocellular Carcinoma, Advanced Solid Tumors With Liver Predominant Locally Advanced/Metastatic Disease or Subcutaneous/Cutaneous Lesions
Phase I Trial of Intratumoral Injection of Vesicular Stomatitis Virus Expressing Human Interferon Beta in Patients With Sorafenib Refractory/Intolerant Hepatocellular Carcinoma, Advanced Solid Tumors With Liver Predominant Locally Advanced/Metastatic Disease or Subcutaneous/Cutaneous Lesions
Enrollment Status: Active_not_recruiting
Publish Date: January 27, 2025
Intervention Type: Other, Biological
Study Drug: Recombinant Vesicular Stomatitis Virus-expressing Interferon-Beta
Study Phase: Phase 1
A Phase IIa, Multicenter, Open-label Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study (KEYNOTE-202)
A Phase IIa, Multicenter, Open-label Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study (KEYNOTE-202)
Enrollment Status: Completed
Publish Date: August 28, 2024
Intervention Type: Drug
Study Drugs: BL-8040, Pembrolizumab, Chemotherapy of Onivyde
Study Phase: Phase 2
A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFPᶜ³³²T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC) or Other AFP Expressing Tumor Types
A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFPᶜ³³²T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC) or Other AFP Expressing Tumor Types
Enrollment Status: Active_not_recruiting
Publish Date: August 15, 2024
Intervention Type: Genetic
Study Phase: Phase 1
A Phase I, Multi-Center, Open Label, Dose De-Escalation and Expansion Study of Gemcitabine and Cisplatin With AG120 or Pemigatinib for Advanced Cholangiocarcinoma
A Phase I, Multi-Center, Open Label, Dose De-Escalation and Expansion Study of Gemcitabine and Cisplatin With AG120 or Pemigatinib for Advanced Cholangiocarcinoma
Enrollment Status: Terminated
Publish Date: May 06, 2024
Intervention Type: Drug
Study Drugs: Cisplatin, Gemcitabine, Ivosidenib, Pemigatinib
Study Phase: Phase 1
A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
Enrollment Status: Active_not_recruiting
Publish Date: April 05, 2024
Intervention Type: Drug
Study Drug: PT-112
Study Phase: Phase 2
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drugs: Bintrafusp Alfa, Gemcitabine, Cisplatin
Study Phase: Phase 2/Phase 3
A Phase II, Multicenter, Open-label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or Are Intolerant to First-line Platinum-Based Chemotherapy
A Phase II, Multicenter, Open-label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or Are Intolerant to First-line Platinum-Based Chemotherapy
Enrollment Status: Completed
Publish Date: October 25, 2023
Intervention Type: Drug
Study Drug: M7824
Study Phase: Phase 2
Phase II Trial of Trifluridine/Tipiracil in Combination With Irinotecan in Biliary Tract Cancers
Phase II Trial of Trifluridine/Tipiracil in Combination With Irinotecan in Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: August 09, 2023
Intervention Type: Drug
Study Drugs: Irinotecan, Irinotecan Hydrochloride, Trifluridine, Tipiracil Hydrochloride
Study Phase: Phase 2
A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients With Advanced or Metastatic Cholangiocarcinoma With FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant to Platinum-based Chemotherapy
A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients With Advanced or Metastatic Cholangiocarcinoma With FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant to Platinum-based Chemotherapy
Enrollment Status: Terminated
Publish Date: July 03, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Single-Arm Feasibility Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk Intrahepatic Cholangiocarcinoma
A Single-Arm Feasibility Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk Intrahepatic Cholangiocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2023
Intervention Type: Drug
Study Drugs: Cisplatin, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 2
A Phase I/II Study of CX-4945 in Combination With Gemcitabine and Cisplatin in the Frontline Treatment of Patients With Cholangiocarcinoma
A Phase I/II Study of CX-4945 in Combination With Gemcitabine and Cisplatin in the Frontline Treatment of Patients With Cholangiocarcinoma
Enrollment Status: Completed
Publish Date: October 22, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 3 Randomized, Open-Label Study Comparing Pexa Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy
A Phase 3 Randomized, Open-Label Study Comparing Pexa Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy
Enrollment Status: Completed
Publish Date: December 16, 2020
Intervention Type: Drug, Biological
Study Phase: Phase 3
Pilot Study of Ponatinib in Biliary Cancer Patients With FGFR2 Fusions
Pilot Study of Ponatinib in Biliary Cancer Patients With FGFR2 Fusions
Enrollment Status: Completed
Publish Date: November 25, 2020
Intervention Type: Other, Drug
Study Phase: Phase 2
A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Enrollment Status: Terminated
Publish Date: July 15, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Pilot Study of a Rapid Access Platform for Investigational Drugs (RAPID) in Advanced Cancers
A Pilot Study of a Rapid Access Platform for Investigational Drugs (RAPID) in Advanced Cancers
Enrollment Status: Completed
Publish Date: June 06, 2019
Intervention Type: Other, Drug
Study Phase: Early Phase 1
A Phase I Study of the Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors
A Phase I Study of the Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: May 11, 2018
Intervention Type: Drug
Study Phase: Phase 1
A Phase Ib, Open-Label, Dose- Escalation Trial of ACY-1215 in Combination With Gemcitabine and Cisplatin in Patients With Unresectable or Metastatic Cholangiocarcinoma
A Phase Ib, Open-Label, Dose- Escalation Trial of ACY-1215 in Combination With Gemcitabine and Cisplatin in Patients With Unresectable or Metastatic Cholangiocarcinoma
Enrollment Status: Withdrawn
Publish Date: May 30, 2017
Intervention Type: Drug, Other
Study Phase: Phase 1
View 18 Less Clinical Trials

222 Total Publications

SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers.
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 13, 2024
Similar Doctors
Elite in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Tanios S. Bekaii-Saab
Hematology Oncology | Oncology | Hematology
Elite in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Tanios S. Bekaii-Saab
Hematology Oncology | Oncology | Hematology

Mayo Clinic Arizona

13400 E Shea Blvd, 
Scottsdale, AZ 
 (0.1 mi)
480-301-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Tanios Bekaii-Saab is a Hematologist Oncology specialist and an Oncologist in Scottsdale, Arizona. Dr. Bekaii-Saab and is rated as an Elite provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Ductal Adenocarcinoma, and Pancreatectomy. Dr. Bekaii-Saab is currently accepting new patients.

Distinguished in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Madappa N. Kundranda
Hematology | Oncology | Hematology Oncology
Distinguished in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Madappa N. Kundranda
Hematology | Oncology | Hematology Oncology

Banner Cancer Center Specialists LLC

1900 N Higley Rd, 
Gilbert, AZ 
 (14.4 mi)
480-543-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Madappa Kundranda is a Hematologist and an Oncologist in Gilbert, Arizona. Dr. Kundranda and is rated as a Distinguished provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Colorectal Cancer, and Familial Colorectal Cancer. Dr. Kundranda is currently accepting new patients.

Distinguished in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Christina S. Wu
Hematology Oncology | Oncology | Hematology
Distinguished in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Christina S. Wu
Hematology Oncology | Oncology | Hematology

Mayo Clinic Arizona

13400 E Shea Blvd, 
Scottsdale, AZ 
 (0.1 mi)
480-301-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Christina Wu is a Hematologist Oncology specialist and an Oncologist in Scottsdale, Arizona. Dr. Wu and is rated as an Elite provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). Her top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Lynch Syndrome, Pancreaticoduodenectomy, and Liver Embolization. Dr. Wu is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile